Loading organizations...
§ Private Profile · Labège, Midi-Pyrenees, France
Biopharmaceutical company developing novel antibacterial resistance-breakers for drug-resistant infections, focused on hospital-acquired infections.
Antabio is a clinical-stage biopharmaceutical company based in Labège, France, that develops novel antibacterial resistance-breakers to treat severe drug-resistant infections. The company creates therapies designed to be co-administered with existing antibiotics to disable bacterial defense mechanisms, targeting conditions such as hospital-acquired nosocomial pneumonia and chronic respiratory infections in cystic fibrosis patients. Operating with an estimated 15 to 50 employees, the enterprise holds 96 patents and has secured over €50 million in total funding to advance its clinical pipeline, including its lead program MEM-ANT3310. This capital includes a €25 million Series B financing round completed in October 2023, which was supported by prominent investors and organizations such as the AMR Action Fund, the EIC Fund, CARB-X, and the Wellcome Trust. Antabio was founded in 2009 by Aymeric Dugray, Helmuth van Es, and Marc Lemonnier.
Antabio has raised $33.0M across 2 funding rounds.
Antabio has raised $33.0M in total across 2 funding rounds.
Antabio has raised $33.0M across 2 funding rounds. Most recently, it raised $26.9M Series B in December 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 12, 2023 | $26.9M Series B | — | Christophe Ricard, AMR Action Fund, BNP Paribas Développement, EIC Fund, Irdi Capital Investissement, Turenne Capital | Announced |
| Jul 12, 2018 | $6.1M Series A Plus | — | BNP Paribas Développement, Galia Gestion, Omnes Capital, Turenne Capital | Announced |
Antabio has raised $33.0M in total across 2 funding rounds.
Antabio's investors include Christophe Ricard, AMR Action Fund, BNP Paribas Développement, EIC Fund, IRDI Capital Investissement, Turenne Capital, Galia Gestion, Omnes Capital.